Skip to main content
Premium Trial:

Request an Annual Quote

Predictive Biosciences Raises $21.75M in Private Financing

NEW YORK (GenomeWeb News) – Predictive Biosciences has closed a Series B financing that has brought in $21.75 million in funding, the Lexington, Mass.-based company said today.
Predictive Bio is developing biomarker-based assays for a variety of cancers, with an initial focus on bladder cancer. The firm also is looking into developing tests for breast, ovarian, prostate, and colorectal cancers.
Predictive Bio said the funds would be used to complete current clinical validation studies and initiate multi-center clinical trials. It also said proceeds would fund efforts to open a CLIA-compliant lab to run diagnostic tests.
The financing round was led by New Enterprise Associates and included Kaiser Permanente Ventures, as well investors from its $10 million Series A round including Flybridge Capital Partners and Highland Capital Partners.
In conjunction with the most recent financing, NEA General Partner James Barrett has joined Predictive Bio’s board of directors, and Kaiser Permanente Ventures Senior Venture Manager Jordan Kramer has been named a board observer.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.